A rare case of coronary artery complication in a child with systemic juvenile idiopathic arthritis and macrophage activation syndrome: case report and literature review
- PMID: 38166957
- PMCID: PMC10759671
- DOI: 10.1186/s12969-023-00944-2
A rare case of coronary artery complication in a child with systemic juvenile idiopathic arthritis and macrophage activation syndrome: case report and literature review
Abstract
A rare case of coronary artery involvement in a child with Systemic Juvenile Idiopathic Arthritis (sJIA) complicated by Macrophage Activation Syndrome (MAS) is reported. The patient initially received an inaccurate diagnosis of Kawasaki Disease, sepsis, and mycoplasma infection and showed no improvement after Intravenous Immune Globulin (IVIG) treatment. Upon admission, symptoms included diffuse red rash, swelling of the limbs, lymph node enlargement, and hepatosplenomegaly. Post investigations, a diagnosis of sJIA and MAS was confirmed, and treatment involved a combination of hormones (methylprednisolone) and immunosuppressive drugs (methotrexate). The revealed widened coronary artery diameter was managed with a disease-specific treatment plan and prophylactic plus low-dose aspirin anti-coagulation therapy. Under this management, MAS was well controlled, and follow-ups showed normalization of the child's coronary artery structure and function. This case and the associated literature review underscore the importance of early recognition, diagnosis, treatment, and long-term monitoring for children presenting with sJIA and MAS complicated by coronary artery involvement.
Keywords: Coronary artery involvement; Macrophage activation syndrome (MAS); Systemic juvenile idiopathic arthritis (sJIA).
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests. No conflicts of interest to disclose. The authors have no financial relationships relevant to this article to disclose.
Figures
Similar articles
-
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.Rheumatol Int. 2016 Oct;36(10):1421-9. doi: 10.1007/s00296-016-3545-9. Epub 2016 Aug 10. Rheumatol Int. 2016. PMID: 27510530
-
A MASsive attack: a pediatric case of macrophage activation syndrome complicated by DIC as an onset of systemic juvenile idiopathic arthritis successfully treated with anakinra and review of the literature.Rheumatol Int. 2024 Nov;44(11):2607-2612. doi: 10.1007/s00296-024-05570-z. Epub 2024 Mar 19. Rheumatol Int. 2024. PMID: 38502236 Review.
-
Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome.Pediatr Ann. 2015 Jun;44(6):e142-7. doi: 10.3928/00904481-20150611-09. Pediatr Ann. 2015. PMID: 26114369 Review.
-
Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis.Clin Rheumatol. 2025 May;44(5):2023-2029. doi: 10.1007/s10067-025-07420-0. Epub 2025 Mar 27. Clin Rheumatol. 2025. PMID: 40146446
-
Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study.Rheumatol Int. 2022 May;42(5):879-889. doi: 10.1007/s00296-021-04980-7. Epub 2021 Sep 7. Rheumatol Int. 2022. PMID: 34491393 Free PMC article.
References
-
- Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 receptor Tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheum. 2017;69(3):668–675. doi: 10.1002/art.39940. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical